On September 10, 2025 Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, reported to share updated overall survival data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up on Thursday, September 25, 2025 (Press release, Immuneering, SEP 10, 2025, View Source [SID1234655921]). The Company additionally shared plans for two presentations at upcoming scientific conferences.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentations:
Updated Overall Survival Data in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP (N=34), with 9 Month Median Follow Up. Immuneering plans to host an investor call at 8 a.m. ET on September 25, 2025. The conference call will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.
Encore Presentation of Updated Overall Survival Data in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP at the PanCAN Scientific Summit. Immuneering plans to present a poster titled "Atebimetinib + mGnP: Overall Survival and Safety in First Line Pancreatic Cancer Patients" on Sunday September 28 at the Pancreatic Cancer Action Network (PanCAN) Scientific Summit 2025 in Boston MA. The presentation will be made from 7:30 – 8:20am and from 12:20 – 1:10pm ET.
Review of Preclinical Data on Deep Cyclic Inhibitors. The Company additionally plans to make an oral presentation titled "Deep Cyclic Inhibition of MEK: A Transformational Approach to Durable and Safe Combinations in RAS-Mutant Cancers" on September 17 at the 7th RAS-Targeted Drug Development Summit taking place September 16-18, in Boston, MA at 4:15pm ET.
"We are excited to share updated overall survival data from our ongoing Phase 2a trial of atebimetinib in combination with mGnP in first-line pancreatic cancer patients. Nine months median follow up is an important milestone because, sadly, less than half of the patients treated with standard of care gemcitabine/nab-paclitaxel in this setting survive 9 months," said Ben Zeskind, Ph.D., Co-founder and Chief Executive Officer of Immuneering. "We previously reported an exceptional 94% OS observed at 6 months in first-line pancreatic cancer patients treated with atebimetinib in combination with mGnP. To put that in perspective, in the pivotal study of standard of care GnP, the 6-month OS was only 67%, and dropped rapidly to approximately 47% by 9 months."
Zeskind continued: "Atebimetinib was designed for durability and tolerability, and we believe it has the potential to deliver what has long been missing in pancreatic cancer care: a drug that helps patients live longer and thrive without serious side effects. PanCAN is a world-class organization dedicated to making life better for pancreatic cancer patients, and so we are excited to share these updates with the oncology community at the PanCAN Scientific Summit 2025."